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Objectives. In patients with familial hypercholesterol­
aemia (FH), the prevalence of haemodynamically 
significant peripheral vascular disease (PVD) was 
measured in relation to lipoproteins, general risk 
factors and the  presence of coronary artery disease 
(CAD).
Design. A case control study.
Setting. The outpatient lipid clinic of a university 
hospital (tertiary referral centre).
Subjects. Patients w ith heterozygous FH [n =  6 8  ; 
age 4 5 .8 ± 1 1 .6  years; untreated LDL-cholesterol
9.2 ± 2 .0  mmol L-1] were compared with control 
subjects m atched for gender, age, weight, smoking 
and presence of hypertension [ n ~ 2 7 \  age 44.0  
years; LDL-cholesterol 3 .8 ± 1 .3  mmoIL"1].
Main outcome measures. PVD was assessed during 
cholesterol-lowering treatm ent using ankle/arm
blood pressure ratios and analyses of Doppler-derived 
blood flow velocities in the femoral artery at rest and 
during reactive hyperaemia. The diagnosis of CAD 
was assessed clinically.
Results. Haemodynamically significant PVD was 
found in 21 (31%) FH patients and in one (3.7%) 
control subject, predominantly localized in the 
femoro-popliteal vessels. CAD was present in 30 
(44.1%) FH patients and in one (3.7%) control 
subject. PVD could be demonstrated in 50% of FH 
patients with CAD [relative risk 3.2 (95% Cl
1 .4 - 7 .2 )] and in 19% as the first manifestation of 
vascular disease. Males and females were equally 
affected. Mean arterial blood pressure of FH patients 
with PVD was higher compared to FH patients 
without PVD.
Conclusions. Haemodynamically significant PVD 
appears to be more prevalent in FH patients than  is 
generally assumed, especially in those with CAD. A 
relation with lipoprotein levels could not be demon­
strated.
Keywords: atherosclerosis, coronary heart disease, 
Doppler spectrum analysis, familial hyper­
cholesterolaemia, peripheral vascular disease.
Introduction
Familial hypercholesterolaemia (FH) is an auto­
somal dom inant disorder caused by one of several 
mutations in the gene on chromosome 19 coding for 
the low-density lipoprotein (LDL) receptor [1, 2]. The 
disorder is characterized by elevated levels of LDL 
cholesterol, tendocutaneous xanthom ata and pre­
m ature coronary artery disease (CAD) [1]. Indi­
viduals homozygous for the genetic defect have 
extremely high serum cholesterol levels and they
mostly develop CAD and peripheral vascular disease 
(PVD) in the first or second decade of life [1, 3]. 
Clinical manifestations of CAD in heterozygous sub­
jects appear in over 50% prior to their fifties; men 
develop CAD in their third to fifth decade and women 
about 10 years later [4, 5]. In contrast, PVD seems to 
occur only at a slightly increased frequency and is 
considerably less prevalent than premature CAD 
[4, 6 ]. The prevalence of intermittent claudication in 
heterozygous FH has been reported as between 8  and 
16% [7-10]. Nevertheless, the occurrence of bruits
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over the femoral arteries have been described more 
frequently [8 , 10, 11]. In a few studies, a decreased 
ank le /arm  systolic pressure ratio has been found in 
62 -65%  of asymptomatic heterozygous FH patients 
[10, 11]. Apparently, PVD in heterozygous FH is 
m uch  more prevalent subclinically, only causing 
symptomatology in advanced cases [ 1 2 , 13].
Sophisticated non-invasive ultrasonic Doppler 
techniques are now available to facilitate the di­
agnosis of PVD. The ank le /arm  systolic pressure 
ratio at rest and  during hyperaemia is a reproducible 
method to determine the presence of arterial 
insufficiency in the lower limbs |.I4], To differentiate 
between haemodynamically significant stenotic 
segments located in the aorto-iliac or the  femoro- 
tibial tract, m easurem ent of an k le /a rm  systolic 
pressure ratio should be combined w ith  the as­
sessment of the haemodynamic status of the aorto- 
iliac tract. Usually, invasive intra-arterial pressure 
m easurem ent in the common femoral artery  in rest 
and during reactive hyperaemia are used to assess 
the functional status of the aorto-iliac tract (the 
‘golden s tan d a rd ’). Several studies have shown that 
these invasive pressure m easurem ents can be 
replaced by analysis of the blood flow velocities in the 
common femoral artery obtained non-invasively by 
Doppler spectrum measurem ents [12, 15]. This 
m ethod has proven to be an accurate, non-invasive 
and easy-to-perform screening-test to assess func­
tionally and haemodynamically significant stenosis 
in the  aorto-iliac tract. Moreover, the  performance of 
Dopper spectrum analyses during reactive hyper­
aemia has been shown to enhance the sensitivity to 
detect haemodynamically significant; aorto-iliac 
pathology [16].
The present study was undertaken to determine 
the prevalence of PVD by non-invasive m easure­
m ents of the ank le /arm  systolic pressure ratio and a 
Doppler spectrum analysis of blood flow velocities in 
the common femoral artery, both at rest and  during 
reactive hyperaemia, in heterozygous FH patients 
and m atched normocholesterolemic control subjects. 
The presence of PVD will be related to lipids and 
lipoproteins, general risk factors, and the presence of 
CAD.
Materials and methods
Subjects
A consecutive series of 72 unrelated  patien ts  know n 
to have definite heterozygous FI I were recruited  from 
the ou tpatien t lipid clinic of the St Radboud Uni­
versity Hospital of Nijmegen, Nijmegen, The 
Netherlands, to which they luid been referred by 
either general practitioners or hospital specialists. 
Four patients refused to take part in the study, one 
because of poor general health. The diagnosis of 
familial hypercholesterolaemia was based on I he 
following criteria: LDL cholesterol above the ninety» 
fifth percentile for sex and age {in general >
8 . 0  mmol L 1 ) ; the absence of a secondary hyperlipo- 
proteinaem ia; the presence of tendon x a n th o m a ta ;  
signs or symptoms of CAD before the age of 5 5 in 
males or the age of 60 in females; a n d /o r  a first- 
degree family m em ber with hypercholesterolaem ia 
or tendon xanthom ata or CAI) before the  age of 55 
and 60 in males and females, respectively. The 
criteria for CAD were the presence of an g in a  (history 
of exercise-associated chest pain), m yocardial in­
farction (proven by electrocardiogram  a n d /o r  serum  
enzyme changes), angiographically proven disease 
or a history of coronary  artery  bypass surgery. 
Hypertension was defined as systolic blood pres­
sure > 1 6 0  m m lfg and diastolic blood pressure
>  90 m m lfg in a supine position at rest. Patients 
with diabetes mellitus were excluded (fasting glucose
>  6.0 mmol L 1 and haem oglobin A 1C' > 6 .4% ). 
The control subjects consisted of 27  volunteers from 
the sam e hospital, m atched for gender, age, weight, 
presence of hypertension and smoking habits, They 
were selected on the basis of their serum  total 
cholesterol levels (below 6.5 mmol L *)« and the 
absence of systemic or metabolic diseases.
Information was recorded from 6 8  FI 1 patients and  
27  control subjects, including the presence of ang ina  
and  in term ittent claudication, details of past medical 
history, family history, sm oking s ta tu s , alcohol 
consum ption, previous trea tm ent for hyperlipo- 
proteinaem ia, and present use of drugs, Medical 
records of the PH patients were used for verification 
of t h i s , information, including previous Hpid and  
lipoprotein levels. Vital signs were m easured, the 
body mass index was calculated, and the presence of 
tendon xan thom ata , xanthelasm as, a rcus  cornealis 
and  peripheral pulsus were noted.
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Lipid and lipoprotein measurements
Fasting concentrations of total cholesterol, serum 
triglycerides, high-density lipoprotein (HDL) chol­
esterol and LDL cholesterol were measured in both 
groups. For the FH group, mean levels of at least two 
measurements w ithout lipid lowering treatm ent and 
four measurem ents during treatment, with intervals 
of 2 -3  m o n th s , were recorded before the vascular 
measurements were taken. Lipoprotein(a) [Lp(a)] 
levels were only measured during hypolipidemic 
drug treatm ent in the  FH group. Serum total 
cholesterol and triglycerides were determined 
by enzymatic methods (CHOD-PAP, no. 237574, 
Boehringer M annheim  GmbH, Mannheim, FRG and 
Sera-PAK, no. 6639, Miles, Milan, Italy, respectively). 
HDL-C was determined using the polyethylene glycol 
6000 precipitation method [17]. LDL-C was calcu­
lated by subtraction. Lp(a) was measured by a 
specific radio-immunoassay [apolipoprotein(a) RIA 
100, Pharm acia Diagnostics AB, Uppsala, Sweden],
Doppler spectrum analysis and ankle/arm systolic 
pressure ratio measurement
In one session, blood flow velocities in the common 
femoral arteries and ank le /arm  systolic pressure 
ratios of both limbs were recorded, both at rest and 
during reactive hyperaemia, as described earlier [16]. 
In short, Doppler signals were obtained from the 
common femoral artery with an 8  MHz bidirectional 
continuous-wave Doppler apparatus (Medasonics 
Inc., M ountain View, CA, USA). The probe was 
placed just below the inguinal ligament. Reactive 
hyperaemia w as induced by thigh cuff compression 
for 5 min at a pressure of at least 50 mmHg above 
the systolic arterial th igh  pressure. Doppler spectra 
during reactive hyperaemia were obtained approxi­
mately 15 s after relief of the thigh compression. 
Doppler signals were processed by a real-time spec­
trum  analyser (Radionics SA8000; Scarborough, 
Ontario, Canada), and subsequently, digitally stored 
on a com puter for off-line analysis. Maximum- 
frequency waveforms were calculated from the 
spectra and several parameters were calculated that 
describe the shape of the waveforms [18]. Based on 
a combination of six of these Doppler parameters 
[duration of the  acceleration phase (Tmax), slope of 
the deceleration phase (SL(lown), maximum frequency
of receding curve (Fmln), and pulsatility index (PI =
Fmax-Fmiii/Finean) at-rest spectra and duration of 
the acceleration phase (Tmax) and resistance index
(RI =  Fmax~Fdia/Fmax) of the spectra during reactive 
hyperaemia], the presence of haemodynamic signifi­
cant aorto-iliac pathology can be assessed accurately 
[16]. The same Doppler probe was used to determine 
the ankle/arm  pressure index, using the systolic 
radial artery pressure and the highest pressure in 
either the dorsalis pedis or posterior tibial artery; the 
side with the highest radial artery systolic blood 
pressure at rest was used as the reference side for 
pressures during reactive hyperaemia. Haemo­
dynamic significant vascular disease was defined as a 
ankle/arm  pressure index at rest <  0 .90 an d /o r  a 
decrease of the pressure index during reactive hyper­
aemia >  0 .2 0 ,
Statistical analysis
Statistical analyses were performed with procedures 
available in the statistical package for social sciences 
(SPSS Inc., Chicago, IL, USA), using Student’s £-test 
or the M ann-W hitney U-test for differences in means, 
and the Yates’ corrected chi-squared test for 
differences in proportions. A P-value of less than  
0.05 was considered to be significant. All results are 
expressed as m ean±SD , unless indicated otherwise.
Results
Subjects
A total of 6 8  patients (29 males and 39 females) with 
heterozygous FH and 27 control subjects (13 males 
and 14 females) were examined, The age distribution 
of the FH population was comparable to the control 
subjects (Fig. 1). The mean ages were 45.8 ± 1 1 . G 
years (range 22 -68  years) for the FH patients and
44.0  ± 1 0 .9  years (range 2 4 -6 4  years) for the control 
group. The main cardiovascular risk factors are 
summarized in Table 1. No significant differences 
were found between the FH patients and the control 
subjects for the body mass index, smoking habits, 
alcohol consumption and hypertension. The presence 
of CAD in the FH population was significantly higher 
than  in the control group, 44.1 versus 3.7%, 
respectively (P <  0.001) (Table 1). Twelve FH 
patients had a myocardial infarction in the past and
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Fig. 1 Age distribution in different cohorts (years) of patients with familial hypercholesterolaemia, with (FHPvn+) ■ ,  and without 
(FHPvnJ  0 ,  peripheral vascular disease, and control subjects □ .
Table 1 Characteristics of all patients with familial hypercholesterolaemia (FHT0TAL), with (FHPVT)+) and without (FHPvnJ  peripheral 
vascular disease, and of control subjects11
Group
Sex
(M/F)
Age
(years)
BMI
(kg m~2)
Smoking
In (%)]
Hypertension 
[" (%)]
MAP
(mmHg)
Angina
[n (%)]
(
ECG-changes 
l>i (%)]
Claudication
[n (%)]
FP1 TOTAu 2 9 /3 9 45.8 +  11.6 2 4 .7 ± 3 ,1 25 (36.7) 7(10 .3) 96 +  11 24(35.3)** 30(44.1)** 1(1.5)
FHPvd+ 8 /1 3 4 7 .6 ± U .Q 25.4 +  3.1 9 (42.8) 4 (1 9 .0 ) 104 ±9**** 11 (52.4)** 15 (71.4)*** 1(1.5)
2 1 /2 6 4 5 .8 + 1 0 .8 24.3 +  3.0 16 (34 .0 ) 3 (6.4) 93 +  11 13 (27.6)* 15(31.9) 0
Controls 1 3 /1 4 44 .0 ±  10.9 2 3 ,7 ± 2 .4 12 (44.4) 2 (7.4) 97 +  9 0 1(3.7) 0
a Values are means± S D  or numbers (percentages); M/F, male/female; BMI, body mass index; MAP, mean arterial pressure (normal 
range 8 0 -1 0 0  mmHg); differences versus control subjects: *0.001 ^  P <  0,001 ; **P <  0.001 ; differences versus FHllvn_: ***0.001 ^  
P <  0.01; 0.001.
1 0  had undergone coronary artery bypass surgery. 
One subject in the control group had a myocardial 
infarction in the past and was free from angina 
pectoris. The cumulative frequency of CAD in FH 
patients as a function of age of onset is shown in Fig. 
2(a). The mean age of onset of CAD in the total FH 
group was 46.3 +  11.1 years (range 2 5 -6 5  years, 
median 45 years), being 41.8 +  10.0 years and
53.2 +  9.1 years for men and women, respectively.
Lipids and lipoproteins
W ithout lipid lowering treatment, mean basal serum 
total cholesterol and LDL cholesterol levels in the 
FH group were strongly elevated (Table 2). HDL 
cholesterol concentrations were significantly lower 
and serum triglycerides did not differ in comparison 
to the control subjects. In the FH group, the 
m ean Lp(a) level of 54.8 +  62.1 mg dL_l (range
© 1995 Blackwell Science Ltd Journal of Internal Medicine 238: 451-459
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Fig. 2(a) The cumulative frequency of coronary artery disease (CAD) in patients with familial hypercholesterolaemia as a function of 
the age onset, (b) The cumulative frequency of peripheral vascular disease (PVD) in patients with familial hypercholesterolaemia as a 
function of the age upon which PVD was detected. □  males, O females.
Table 2 Basal and treatment levels of lipids and lipoproteins, type and duration of lipid lowering treatment of all patients with familial 
hypercholesterolaemia (FHT0TAL, n — 68), with (FHPVD+I n =  21) and without (FI-IIJVD„, n =  47) peripheral vascular disease, and of 
normocholesterolemic control subjects (/i =  27)il
Group
Total
cholesterol 
(mmol L"1)
HDL-cholesterol 
(mmol L“1)
LDL-cholesterol 
(mmol L_1)
Triglycerides 
(mmol L”1)
Lp(a)
(mg dL“1)
Medication
(inhibitor/resin)
Treatment
(years)
PH *
TOTAL': basal 11,11 ± 1 .8 4 * 1.09 +  0.32* 9.19 +  2.03* 1 .7 7 ± 0 .7 3 ---------- ----------
treatment 7.35 ±  1.30* 1,18 +  0.33* 5.51 +  1.35* 1.50 +  0.62 54.8 +  62.1 6 1 /2 8 5.5 ±  3.7
f h p v d + : basal 11.37 +  1.79 1.17 +  0 .27 8 .7 3 ± 2 ,0 8 1.84 +  0.42 ---------- ---------- ----------
treatment 7.51 +  1.32 1.26 +  0.34 5.54 +  1.39 1.63 +  0.67 50.3 +  49.0 2 1 /5 5.2 ±  3.2
™ PVD_: basal 10.93 +  1.85 1.06 +  0.33 9 .1 9 ± 2 .0 9 1.75 +  0.82 ---------- ---------- ----------
treatment 7 .2 8 ±  1.28 1 .1 5 ± 0 ,3 2 5.49 +  1.33 1.45 +  0.61 5 7 .0 ± 6 8 .1 4 0 /2 3 5.6 +  3.9
Controls 5.79 +  1.47 1.41 +  0.40 3.75 +  1.30 1 .6 1 ±  1.25 ---------- ---------- ----------
aValues are m eans+  SD; H(L)DL-chol, high (low)-density lipoprotein cholesterol; Lp(a), Lipoprotein(a); inhibitor/resin, number of 
patients on HMG-CoA reductase inhibitors and/or resins, respectively; differences versus control subjects: *P ^  0.001; no significant 
differences were found between FHPVD+ and FHPVD_.
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Table 3 Prevalence of haemodynamically significant peripheral vascular disease (PVD) and Doppler spectrum waveform characteristics 
at rest and after reactive hyperaemia in patients with familial hypercholesterolaemia in comparison to normocholesterolaemic control
subjects'1
Familial hypercholesterolaemia
PVDAr+ PVD,,t+ PVD — Controls!
Number (%) 5 (7.4) 1 6 (2 3 .5 ) 47 (69.1) 26 (96.3)
At rest
AAI 0 ,9 2 ± 0 .1 5 * 0 ,9 3 ± 0 .1 2 1 .05±0 .1Q l .Q 9 ± 0 .1 2
Fm„  (Hz) 4 0 8 7 ± 9 3 4 * 7 1 7 7 ± 2 6 4 5 6909 ± 2 0 7 7 6 9 2 4 ± 2 4 9 6B HilA
FmlIl (Hz) —1314 +  991 —1622 +  405 —1 8 5 7 ±  626 - 1 8 2 7 ± 6 3 0
SI,...... (m s"2) — 21 +  7* - 3 6  +  8 — 33 ± 1 3 — 3 5 ±  14
Tmas (ms) 129 ±24** 1 0 2 ±  17 101 ±  16 100 ± 2 4
PI 4.03 ± 1 .9 6 5.01 ± 1 .4 9 5 .0 0 ± 1 .2 7 4.96 ±  1 .64
After hyperaemia
AAI 0,75±0.17** 0 .7 7 ± 0 .0 7 o . 9 5 ± o . n 0 .9 6 ± 0 .0 8
T.uax <mS) 133 ±  54 1 0 0 ± 3 9 1Q 5± 36 98 ±  32 1
RI 0 ,6 0 ± 0 .1 0 0.65 ± 0 .0 8 0.68 ± 0 .1 0 0.68 ± 0 .0 8
11 Values are means±SD or numbers (percentages); PVDAI+, aorto-iliac pathology; PVDFT+, femoro-tibial pathology; PVD—, no 
peripheral vascular disease; AAI, ankle-arm pressure ratio; for explanation of Doppler parameters see ‘Materials and methods’ section. 
fOne patient with PVD is excluded, Differences versus FH,,VD_ and control subjects: *0.01 ^  P < 0 .05; **0.0001 ^  P <  0 .01.
3.4-336 .0  mg dL“1, median 25.4 mg dL"1) was 
higher than expected in normolipidaemic volunteers 
[19]. All FH patients were treated with lipid lowering 
drugs for a mean period of 5.5 ± 3 .7  years (range
0 .6-15  years, median 4.7 years); 61 out of 6 8  
(89.7%) patients were treated with a 3-hydroxy-3- 
methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitor (simvastatin or pravastatin), 28 out of 6 8  
(41.2%) used a resin (cholestyramine or colestipol), 
and 21 out of 6 8  (30.9%) a combination of both 
groups of drugs (Table 2). During lipid-lowering 
treatment, the levels of total cholesterol, LDL chol­
esterol and HDL cholesterol in the FH group were still 
significantly different in comparison with the control 
subjects (Table 2).
Peripheral vascular disease
Vascular measurements were performed during lipid- 
lowering treatment. The ankle/arm  pressure ratios 
at rest were 1.03 ± 0 ,1 2  and 1,08 ± 0 .1 1  (P =  0.05), 
and 0 .8 9 ± 0 .1 3  and 0 .9 5 ± 0 .0 9  (P =  0.03) after 
reactive hyperaemia for all the FH patients and 
control subjects, respectively. One FH patient was 
known to suffer from intermittent claudication (a 
female; first symptoms at 38 years of age). Twenty- 
one out of 6 8  (30.9%, eight males and 13 females) 
FH patients had a pathological low ankle/arm  
systolic blood pressure ratio bilaterally or unilaterally 
(Table 3). In 39 out of 136 (28.6%) limbs, the
pressure index was abnormal, so three patients 
exhibited a low ratio in only one leg. The patients 
with PVD were distributed equally w ithin the 
different age groups (Fig. 1). The youngest patients 
with haemodynamically significant PVD were 31 
years old (a =  3) and most patients w ere found in the 
4 0 -4 9 -year-old age cohort. The m ean age a t which 
PVD was found for the total group, namely 
4 7 .2 ± 1 1 .0  years (range 3 1 -6 4  years, median 4 7  
years), was not different for m en and women 
(4 7 .8 ± 1 2 .4  and 4 6 .8 ± 1 0 .6  years, respectively). 
The cumulative frequency of PVD as a function of the 
age of detection is shown in Fig. 2(b). The total 
frequency in the male population of 27.6% (8 /2 9 )  
was not significantly different w hen compared with 
33.3% (13 /39 ) in females.
Peripheral vascular disease was predominantly 
found in the femoro-tibial region in 16 out of 2 1  
(76.2%) patients (Table 3). Eight of these 16 patients 
with a decreased ankle/arm  index of <  0 .90  and a 
normal Doppler spectrum were detected by m easure­
ments at rest, and the remaining eight patients had 
a decrease in the pressure index of ^  0 . 2 0  during 
reactive hyperaemia. Peripheral vascular disease in 
the aorto-iliac vessels, showing an  abnorm al Doppler 
spectrum of the femoral artery, was found in five out 
of 21 (23.8%) FH patients with a decreased ank le / 
arm index. Some parameters of the Doppler spectrum 
waveforms are shown in Table 3. Post-stenotic 
waveforms in patients with aorto-iliac pathology are
© 1995 Blackwell Science Ltd Journal of Internal Medicine 238: 451-459
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characterized by a  decreased maximum frequency 
shift (Fmax) and resistance index (RI), and an increase 
in the duration of the acceleration phase (Tmax) 
[16, 20]. Only one o u to f 2 7  (3.7%, afemale) control 
subjects had  significant changes in the femoro-tibial 
tract, showing bilaterally pathological pressure in­
dexes at rest and norm al Doppler spectra. Comparison 
of the prevalence figures of PVD in the FH group and 
the control subjects showed significant differences, 
either expressed per patient (P =  0,01) or per limb 
(P <  0.001).
Characteristics of the FH patients with and without 
PVD are shown in Tables 1 and 2. No differences 
were found with regard to gender, age, body mass 
index, smoking habits, alcohol consumption, lipids 
levels (basal or during lipid lowering treatment), 
Lp(a) concentrations, and the duration and the type 
of administered lipid lowering drugs. Hypertension in 
the medical history of the FH patients with PVD was 
found more often. Only the m ean arterial blood 
pressure before the vascular measurements was 
significantly higher in comparison with the patients 
without PVD: 104 ±  9 mmHg versus 93 ±  11 mmHg 
(P < 0.001), respectively. A tendency was observed 
in the FH patients with PVD to have more clinical 
symptoms of CAD (angina pectoris) th an  in those 
without PVD. Only ECG-changes at rest or during 
exercise tests had a significantly greater presence in 
the group with PVD: 71.4% versus 31.9% (P =
0.006), respectively. Thirty out of 6 8  (44.1%) of the 
total group of FH patients had CAD, 15 (50%) of 
whom had abnorm al pressure indexes, whereas only 
six out of 38 (19%) patients w ithout CAD had PVD. 
Therefore, the relative risk of finding haem o­
dynamically significant PVD of the lower extremities 
in FH patients w ith signs or symptoms of CAD 
compared with FH patients w ithout CAD is 3.17 
(95%, confidence limits 1 .40-7 .17).
Discussion
Peripheral vascular disease in population studies is 
unequivocally associated with dyslipoproteinaemia 
[21, 22]. Our study addressed the question of the 
prevalence of PVD given the presence of well-defined 
FH. In FH populations, PVD has been reported in 
only 1.5% of cases as the first manifestation of 
vascular disease, whereas symptoms of CAD are the 
first feature in 94% [7]. In a prospective cohort study 
in subjects with heterozygous FH in England and
Wales, a prevalence of intermittent claudication in 
the 40-59-year-old age group has been found in 8 . 8  
and 9.7% of men and women, respectively [23]. In 
the present study, using non-invasive measurements, 
haemodynamically significant lesions were present 
in approximately one out of three asymptomatic FH 
patients, and PVD was the first atherosclerotic 
manifestation in 19%. Of course, studies based on the 
detection of symptoms yield lower prevalence figures 
th an  those using non-invasive measurements, 
whereas the latter show intermediate figures w hen 
compared to studies using invasive angiographic 
methods [22, 24, 25].
The haemodynamically significant PVD prevalence 
figure of 31% seems lower than  has been shown by 
others using pressure ratio index measurements 
[10, 11]. However, a higher cut-off point for a 
pathological ankle/arm  pressure ratio index of 
< 0 .9 7  has been used in these studies, and this 
may have overestimated the presence of PVD, since 
the use of a cut-off point of < 0 .9 0  appears to  be 
more predictive for significant obstruction [26].
In the past few years, there has been an increasing 
use of B-mode ultrasound in the assessment of 
atherosclerotic changes by measuring the intima- 
media thickness in the carotid and remoral artery 
[27, 28]. This method may show early athero­
sclerotic manifestations of the intima-media complex 
which will not interfere with flow in contrast with 
Doppler spectrum analysis. However, haem o­
dynamically significant changes in blood flow are 
comparable for both methods: in a recent study 
using B-mode ultrasound assessment in patients 
with heterozygous FH, plaques causing haem o­
dynamically significant changes in blood flow in the 
femoral artery were found in 14 out of 36 (39%) 
patients, a figure that is comparable to that found in 
the FH population of our study [28].
There is considerable variability in the clinical 
manifestation of patients with heterozygous FH [1]* 
The phenotypic expression may be influenced not 
only by differences in the underlying mutation, the 
apolipoprotein E phenotype, lipid and lipoprotein 
levels, and susceptibility to oxidative modification of 
LDL, but also by general risk factors such as gender, 
obesity, hypertension and smoking [5, 6 , 29 -32]. In 
our study, no significant differences between the FH 
patients with and without PVD were found with 
regard to lipid and lipoprotein levels and general risk 
factors, w ith the exception of a higher blood pressure
© 1995 Blackwell Science Ltd Journal of Internal Medicine 238: 451-459
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before the vascular measurements. Therefore, mod­
erate hypertension may have increased the risk of 
development of PVD in the group of FH patients we 
studied,
in those with CAD. Males and females are equally 
involved, and the preferential localization in the 
femoro-popliteal vessels was not related to the 
lipoprotein levels or general risk factors in this small
The present study also showed that PVD was group of patients, with the exception of hypertension.
mainly found in the femoro-tibial segments and less 
in the aorto-iliac vessels. Using strain-gauge plethys­
mography, Koivosto et ni. also demonstrated the 
predominant affection of the proximal lower limb 
arteries in FH [10]. However, Rubba et a l have 
shown predominantly aorto-iliac pathology in FH 
using Doppler spectrum analysis of the common 
femoral artery at rest [33]. Using ultrasound methods 
as described in our study, only haemodynamically 
significant lesions (stenosis ^  50%) causing a de­
crease in arterial pressure or flow are documented, 
and addition of analyses during hyperaemia in­
variably increases the sensitivity of this method [16].
Therefore, the ultrasound measurements at rest of 
previous studies may have underestimated the pres­
ence of PVD. Since Doppler spectrum analysis at rest 
and during reactive hyperaemia accurately demon­
strates the presence of aorto-iliac disease, even if 
atherosclerotic lesions of the femoral artery in 
multilevel occlusive disease exist, the presence of 
haemodynamically significant aorto-iliac pathology 
is probably not underestimated in our study [34].
Therefore, the primary predilection side of PVD in FH 
seems to be the proximal lower limb arteries or the 
femoral-popliteal segment. Generally, a comparison 
between the age of onset of symptoms of CAD and the 
age at which PVD was detected in this study is 
debatable, Still, CAD and PVD can be found only 
when haemodynamic significant atherosclerotic 
lesions are present. Indeed, manifestations of CAD 
can occur coexistent with PVD in FH patients 
[5, 1 1 , 13, 25]. Our study showed tha t some patients 
develop CAD and PVD as early as the third decade of 
life, and that the mean age of onset of CAD was 
comparable to the mean age upon which PVD was 
detected (46 versus 47  years, respectively). Moreover,
50% of the patients with established CAD also 
exhibited PVD, whereas only 19% of the patients 
without CAD showed PVD. Therefore, these data 
show that there is a three-fold relative risk for 
(asymptomatic) PVD once a patient with hetero­
zygous FH exhibits signs or symptoms of CAD.
In conclusion, haemodynamic significant PVD in 
patients with heterozygous FH is m uch more preva­
lent than is expected on clinical grounds, especially
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